Fulcrum Therapeutics - Q3 2024

Executive Summary

• Q3 2024 was a transition quarter: no collaboration revenue, narrowed operating spend, and reaffirmed a strong balance sheet ($257.2M cash/marketable securities; runway into at least 2027), while the program pivot to pociredir in SCD accelerated post-REACH failure and workforce reduction.
• EPS of $(0.35) diluted improved YoY from $(0.39); operating loss narrowed to $(25.1)M vs $(27.4)M YoY; R&D and G&A declined YoY (cost-sharing reimbursements and workforce actions).
• Guidance: end-2024 cash ≈$240M; 2025 cash burn guided to $55–$65M; runway “into at least 2027” maintained; management emphasized pociredir as fully funded through key 2025 data readouts.
• Stock reaction catalysts: suspension of losmapimod (Sept) and sharpened focus on pociredir; initiation of healthy volunteer studies and expectation to guide timing for PIONEER Cohort 3 (12mg) and Cohort 4 (20mg) data early 2025; OXBRYTA® withdrawal heightens urgency for oral SCD options.

What Went Well and What Went Wrong

What Went Well

• Management executed the pipeline pivot: PIONEER enrollment and site activation progressing; Cohort 3 at 12mg O.D. underway followed by Cohort 4 at 20mg O.D.; up to 10 patients per cohort; data planned in 2025. “We are focused on progressing the development of pociredir as expeditiously as possible…”.
• Balance sheet strength preserved: cash/marketable securities $257.2M; other income $3.43M; runway into at least 2027, even after program shift and restructuring.
• Cost discipline: R&D down to $14.6M (from $18.2M YoY) on Sanofi cost-sharing reimbursements; G&A lowered to $8.4M (from $10.0M YoY) on workforce reduction.

What Went Wrong

• Losmapimod Phase 3 REACH failed primary and secondary endpoints; program suspended, removing a near-term commercialization path and creating execution risk around a single lead program (pociredir).
• No collaboration revenue in Q3 (vs $0.8M in Q3 2023), reflecting completion of prior MyoKardia work; net loss remains significant at $(21.7)M.
• Restructuring expenses of $2.063M recorded in Q3 tied to workforce reduction; also, reliance on ex-U.S. sites for SCD trials requires high-quality data/GCP compliance—management provided comfort but it remains a diligence watch-item.

Transcript

Operator (participant)

Good morning and welcome to Fulcrum Therapeutics' third quarter 2024 financial results and business update conference call. Currently, all participants are in a listen-only mode. This call is being webcast live and can be accessed on the investor section of Fulcrum's website at www.fulcrumtx.com and is being recorded. Please be reminded that remarks during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. May include statements about the company's future expectations and plans, clinical development timelines, and financial projections. While these forward-looking statements represent Fulcrum's views as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future but is not taking on an obligation to do so.

Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for discussions of certain risks and uncertainties associated with the company's business. Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer; Dr. Pat Horn, Chief Medical Officer; and Dr. Iain Fraser, Senior Vice President of Development. After providing updates on our key programs, there will be a brief Q&A in which Alex, Alan, Pat, and Iain will be available to answer your questions. With that, it's my pleasure to turn the call over to Alex.

Alex Sapir (CEO and President)

That's great. Thanks, Michelle, and good morning, everyone. I appreciate you joining us for our third quarter conference call. Today, I'll provide you with updates on recent progress and upcoming milestones. I'll then hand the call over to Alan to review financials, and finally, we'll end by taking your questions. I'll begin with a very brief review of the update we provided on the losmapimod program back in September. As you'll recall, we reported that losmapimod did not show separation from the placebo group on the primary or key secondary endpoints in the phase III REACH trial. In light of these results, we suspended the development of losmapimod and announced a workforce reduction of approximately 40% in order to focus our research and development efforts on advancing pociredir and our preclinical pipeline.

This included a reduction of positions across both research and development, as well as general and administrative functions. I do want to take a moment to express my gratitude to the patients, physicians, and clinical coordinators who participated in our trials, to the FSHD Society, and to the broader FSHD community. We sincerely appreciate all of your support in advancing the losmapimod program, and we remain fully committed to sharing the full results of the REACH trial for the benefit of the FSHD community. Although we were disappointed that the phase III results did not replicate what was shown in phase II, the entire Fulcrum organization remains deeply committed to our mission of improving the lives of patients with genetically defined diseases in areas of high unmet need.

To that end, we are excited to continue advancing pociredir, our oral HbF inducer, for the potential treatment of patients with sickle cell disease. Sickle cell disease is a lifelong inherited blood disorder that severely impacts quality of life for approximately 100,000 people in the U.S. and approximately 4.4 million people worldwide. Historically, the standard of treatment for patients with sickle cell disease has involved blood transfusions, pain medications, and hydroxyurea, focusing primarily on symptom relief. Despite the recent approval of gene editing approaches, we believe there remains a significant unmet need for safe and accessible oral therapeutic options that are broadly protective of sickle cell symptomatology, which is further underscored by the recent global withdrawal of Oxbryta. As a first-in-class oral small molecule HbF inducer, we believe that pociredir has the potential to address this unmet need.

Now, in our phase I-B trial of pociredir, which we call the Pioneer trial, we continue to make progress in enrolling patients and activating sites. We are focused on progressing the development of pociredir as expeditiously as possible and remain on track to provide data from the Pioneer trial in 2025. Based on our progress in site activation and current enrollment trends, we intend to provide more detailed guidance on our plans to share data early in the new year. As a reminder, Cohort III of the trial is evaluating pociredir at the 12 mg once-daily dose with a dosing duration of three months, and this will be followed by Cohort IV at the 20 mg once-daily dose also for three months. Both cohorts are expected to enroll up to 10 patients.

In addition to the ongoing Pioneer trial, we are also pleased to report that we are initiating phase 1 clinical trials of pociredir in healthy volunteers following recent interactions with the FDA. These studies are intended to support the comprehensive development program for pociredir. The literature supports that any increase in fetal hemoglobin is beneficial for patients with sickle cell disease. Most importantly, when sickle cell patients achieve fetal hemoglobin levels in the mid- to high 20s, their disease presentation may become asymptomatic. We believe that as a novel inducer of fetal hemoglobin, pociredir has the potential to provide a differentiated therapeutic option for people living with sickle cell disease. We look forward to building on the encouraging clinical data generated prior to the hold, which demonstrated that pociredir increased total fetal hemoglobin of a magnitude that could translate into meaningful improvements in disease severity.

Now, beyond pociredir, we are also focused on advancing our early-stage development programs in inherited aplastic anemias such as Diamond-Blackfan Anemia, or DBA, Shwachman-Diamond syndrome, or SDS, and Fanconi anemia under our licensing agreement with CAMP4. We anticipate sharing additional information regarding a development candidate and plans for IND-enabling studies in the near future. I also wanted to provide some updates on the management and board of directors front. This morning, we announced that Rachel King has joined our board of directors. Having served as the CEO at BIO, executive in residence at NEA, as well as CEO of several early-stage biotech companies, Rachel's experience is well aligned with Fulcrum's needs given where we are in our evolution. She currently serves on the board of Novavax and GlycoMimetics.

Rachel will be replacing Jim Collins, who will be transitioning to an advisory role on our Science and Technology Committee. I am personally excited to have Rachel joining us and also pleased that we will continue to benefit from Jim's deep scientific acumen and sound judgment. Now, on the management front, Dr. Thomas Winkler joined us in September as our Vice President of Hematology Clinical Development and has assumed responsibility for our hematology program, but also for the Pioneer study. Thomas has a distinguished career within the hematology branch of the NIH before transitioning to industry, where he focused on developing numerous hematology assets at both Agios and AstraZeneca. Additionally, Pat Horn, our Chief Medical Officer, has decided to retire at the end of this year.

Pat joined Fulcrum earlier this year and was instrumental in leading clinical development for the REACH study, hiring key talent like Thomas, and building out the medical team as we prepared for the launch of losmapimod. I would like to personally thank Pat, who is here with us in the room today. Thank you, Pat, as well as express my appreciation to Thomas for bringing his strong hematology background to Fulcrum at such a critical time. And with that, I will now turn it over to our Chief Financial Officer, Alan Musso, to run through the numbers. Alan, over to you.

Alan Musso (CFO)

Thanks, Alex. I'll now review our financial results, starting with our cash position. As of September 30th, 2024, cash, cash equivalents, and marketable securities were $257.2 million compared to $236.2 million as of December 31, 2023. The increase in our cash position is due to the $80 million upfront payment that we received from Sanofi in the second quarter, partially offset by cash used to fund our operating activities in 2024. We had no collaboration revenue in the third quarter of 2024 compared to $0.8 million for the third quarter of 2023. The decrease of $800,000 was due to the completion of our research services under our collaboration agreement with MyoKardia during the fourth quarter of 2023. Our research and development expenses were $14.6 million for the third quarter of 2024 compared to $18.2 million for the third quarter of 2023.

The decrease of $3.6 million was primarily due to the global development cost-sharing reimbursement under our collaboration with Sanofi for losmapimod, partially offset by increased costs related to the advancement of our phase I-B Pioneer trial. General administrative expenses were $8.4 million for the third quarter of 2024 compared to $10 million for the third quarter of 2023. The decrease of $1.6 million was primarily due to decreased employee compensation costs as a result of our reduction in workforce implemented in the third quarter of 2024. The net loss was $21.7 million for the third quarter of 2024 compared to a net loss of $24 million for the third quarter of 2023. Finally, turning to our cash guidance, we expect to end 2024 with approximately $240 million of cash, cash equivalents, and marketable securities.

We expect that in 2025, our cash burn will be approximately $55 million-$65 million. Based on current operating plans, we expect that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operating requirements into at least 2027. With that, let me turn the call back over to you, Alex.

Alex Sapir (CEO and President)

Okay, great. Thanks so much, Alan. I think with that overview of the business and the financials, Michelle, why don't we go ahead and open it up for questions?

Operator (participant)

Thank you. To ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. And our first question will come from Matthew Biegler with Oppenheimer. Your line is now open.

Matthew Biegler (Managing Director)

Hey, guys. Thanks for the update this morning. Maybe just a high-level question, Alex, on the platform tech and how you're thinking as we seed in the pipeline with new wholly owned assets. How do you think about the difference between keeping it wholly owned versus partnering something out? And for maybe next-gen assets, are there certain disease therapeutic areas that you want to focus in? I mean, should the focus be hematology going forward, or are you kind of open to exploring new avenues? Thanks.

Alex Sapir (CEO and President)

Yeah, it's great, Matt. Thanks so much for the question. Yeah, so we do have a very rich preclinical pipeline. I would say that the most advanced preclinical program that we have, as I mentioned during the prepared remarks, is our program that we have for inherited aplastic anemias, which do include DBA, Shwachman-Diamond syndrome, or SDS, Fanconi anemia, 5q- syndrome. And we do expect to announce more updates in the near future around the selection of a development candidate and IND-enabling studies. So that is by far our most advanced program. And as you know, came from the deal that we signed with CAMP4 in September of last year. We do have the global rights for those. I think for the time being, we are going to continue to progress those ourselves.

And then obviously, there is always an option for potential licensing for potentially markets outside of the U.S., similar to what we did with the Sanofi deal with losmapimod. But right now, our focus is really on progressing some very, very interesting work that we've got going on in our discovery efforts. Most notable is the work we're doing in some of these inherited aplastic anemias that I mentioned. Iain, anything you would add to that?

Iain Fraser (SVP of Development)

No, I think that covers the ground pretty comprehensively.

Matthew Biegler (Managing Director)

Okay. Thanks, guys. Appreciate it.

Alex Sapir (CEO and President)

Yeah, thanks, Matt.

Operator (participant)

And our next question will come from Dae Gon Ha with Stifel. Your line is open.

Dae Gon Ha (Director of Biotechnology Equity Research)

Great. Good morning, guys. Thanks for taking our questions and congrats on the progress. I guess two questions on pociredir specifically. Going back to your 10-Q filing, it seems like on the risk section, you have been having this information or the language around request for information to define the potential risk in any further studies that may be conducted in healthy volunteers. You are announcing your intention to do another healthy volunteer study. So curious, what exactly was the feedback from the FDA post-Oxbryta withdrawal that led you to having this trial run sort of concurrent with the Pioneer study? And then second, I guess, in terms of the African conduct, just curious, what have been sort of the latest FDA feedback on whether or not that meets the standards for the FDA review? Thanks so much.

Alex Sapir (CEO and President)

Sure. Yeah, thanks, Dae Gon Ha, so much for the question. And I'll probably add a little bit of color on the first question, punt that over to Iain. And then as it relates to the second question around African continent, I'll punt that over to Pat. Yeah, so I think just to remind everybody on the call, when we did get off clinical hold, there was no additional clinical or preclinical data that the FDA required prior to going into patients. There was some additional work that the FDA did require of us in order to progress with healthy volunteers.

Based on the discussions that we've had with the agency, we are, as I mentioned in the prepared remarks, we are moving forward with the work that we need to do in healthy volunteers to really inform the overall clinical development plan and the eventual package that will become the NDA. But I think more specifically, let me turn that over to Iain maybe to get into a little bit more detail.

Iain Fraser (SVP of Development)

Yes, thanks, Alex. Thanks, Dae Gon Ha, so I think important to recognize that these healthy volunteers studies were our studies that have been planned all along. They're part of the routine development of a compound. They're studies that look at evaluations of new formulations as they get introduced into the clinic, some of the drug-drug interaction studies, and studies to more finely delineate the metabolism and excretion of the compound. So those are standard drug development studies that were always part of the program. As Alex mentioned, there was this differentiation at the time of the clinical hold between the patient studies, and resuming patient studies was entirely around redefining that patient population and balancing risk-benefit and then on the healthy volunteer side was segregated out because, of course, there's no benefit to individuals participating in healthy volunteer studies.

We've performed those and are now progressing with the studies as part of the overall development plan. It's really coincidental around the timing of the Oxbryta withdrawal. There's no link between resumption of those studies and the Oxbryta withdrawal.

Alex Sapir (CEO and President)

Yeah. And then, Dae Gon Ha, as it relates to your second question before turning it over to Pat, I think maybe just real quickly, for some of the patients that we have enrolled to date, they are coming from African countries. And I will say that we've actually been pretty pleased with some of the compliance that we've seen to date. In terms of the regulatory take on patients coming from sites in Africa, maybe I'll turn that one over to Pat to provide a little bit more detail.

Pat Horn (CMO)

Yeah. The FDA has a long history of accepting data from ex-US sites. In fact, most of the large phase III studies now are global sites. In diseases such as sickle cell anemia, where the population is really concentrated in different geographies, there's a long history. I think the majority of studies in sickle cell that have led to approval and that are currently ongoing in phase II and phase III have included sites in sub-Saharan Africa, especially. The FDA is really only concerned about the quality data and that they follow GCP. As part of our progress and ongoing activities in the study, we review each of these sites before we select sites that have experience. Most of them have experience in previous sickle cell studies. Most of the sites we're looking at have been audited by regulatory agencies, some even by the FDA.

We feel confident in the sites we've selected and their ability to produce acceptable data for the phase I study and even for future registration studies.

Dae Gon Ha (Director of Biotechnology Equity Research)

Great. Thanks for taking our questions. Oh, sorry.

Alex Sapir (CEO and President)

No worries. Thanks, Dae Gon Ha. Thanks so much. Operator, next question.

Operator (participant)

And our next question will come from Edward Tenthoff with Piper Sandler. Your line is open.

Edward Tenthoff (Managing Director and Senior Research Analyst)

Great. Good morning, everyone. And thanks for taking my question. So following up on Dae Gon Ha's questions, I wanted to get a little sense in terms of can you provide any better guidance on how this data from Pioneer may roll out next year? Will you report it all together? Would you split the 12 and the 20 mg and kind of report it out as it's available? And how quickly do you envision being able to transition from that into a registrational study? Thank you.

Alex Sapir (CEO and President)

Yeah, that's great. Thanks so much for asking the question. I'll address the first part of your question, excuse me, and then I'll turn it over to Pat to address the second part of your question. Yeah, so as we've said in the past, we do intend to share the 12 mg cohort, which is being run sequentially to the 20 mg. So those two data sets will come out at different points in time in 2025. And so we do intend to share those independent of one another. We are pleased with the progress that we are seeing right now with enrollment. We absolutely have the right sites that are now in place, and we're continuing to add new sites. And as we've always said, once we build that critical mass of patients, we'll come back to everybody with more specificity, specifically when in 2025 we'll have data to share.

So I think right now it is a bit premature to give any more specific guidance. But as I said in some of my prepared remarks, we do intend to provide more detailed guidance on our plan to share data early in the new year in early 2025. So I think more specifically about your question in terms of what's the next study after this, maybe I'll turn that one over to Pat.

Pat Horn (CMO)

Yeah. So Thomas Winkler, since he's been here, he's been working with our head of regulatory and our regulatory group to really define the clinical development program for pociredir following this phase I-B. And there are multiple possibilities. Since we have orphan drug designation, we are entitled to an end-of-phase 1 study with the FDA, which we plan to make use of. So we'll take the data from the Pioneer study, propose a clinical development plan to the FDA, and then get their agreement. And that may be the ability to move quickly to a phase II, phase III study, which may be registrational, or it may be a separate phase II followed by a phase III study. But that will depend on the data from Pioneer and the feedback from the FDA.

Alex Sapir (CEO and President)

Yeah. And then, Ted, maybe the only other thing that I would add is the abundance of evidence to show that increases in fetal hemoglobin improves not only symptomatology in terms of reduction in VOCs, but also overall survival. And as we've said and shared with you many times, once you get patients over that sort of mid to high 20s, their disease does become asymptomatic. So I think there is certainly internal discussion going as well as to when is the right time to discuss fetal hemoglobin potentially as a surrogate endpoint that we may use in one of our further studies for the Pioneer development program.

So that work is still ongoing, but I think that is an important point to make just because how strongly the relationship is based on the data that is out there to show that increases in fetal hemoglobin have a very, very noticeable impact on survival as well as reduction in VOCs.

Edward Tenthoff (Managing Director and Senior Research Analyst)

Yeah. Makes a lot of sense. Great. Thank you so much for the call. I look forward to seeing you in just a couple of weeks here.

Alex Sapir (CEO and President)

Yeah, it's great. Thanks so much, Ed. Operator, next question.

Operator (participant)

Our next question comes from Kristen Kluska with Cantor Fitzgerald. Your line is open.

Rick Miller (VP of Biotech Equity Research)

Hi everyone. This is Rick Miller on for Kristen. Thanks for taking our question. Just a quick follow-up on the healthy volunteer studies you talked about initiating. How are you thinking about dosing in these trials? And how does this relate to kind of the previous phase I trial dosing strategies you looked at? And in terms of main outcomes here, will this be mostly looking at safety, or are there any kind of PK/PD measures you're interested in getting a look at? Thank you.

Alex Sapir (CEO and President)

Yeah, it's a great question, Rick. I think to answer that, let me kick that one over to Iain.

Iain Fraser (SVP of Development)

Yeah, thanks, Rick. The studies are predominantly looking at PK profiles in this case, both from the perspective of the ADME, the absorption, distribution, and metabolism of the drug. It's a standard radiolabel study that gets done in development. So that's one of the studies that's teed up measuring the drug in the blood and the excretion in the urine and the stool, for example. And then the other studies are primarily focused on measuring the PK. So new formulations as they come into development will be given to healthy volunteers. And they're typically single-dose PK studies where you measure the performance of the new formulation and compare it to the older formulation. And for the drug-drug interaction studies, it's giving pociredir in the presence of other agents that are commonly used in order to evaluate any impact on the plasma pharmacokinetics of the drug.

Those are the studies that are in line as part of the overall development program and what we'll be doing. We obviously look at safety and tolerability as a key endpoint in all of those studies. The important driver of the results that goes back to inform the clinical program and the patients is around the PK.

Rick Miller (VP of Biotech Equity Research)

Thank you.

Alex Sapir (CEO and President)

Yeah. Thanks, Rick. Operator, next question.

Operator (participant)

Our next question comes from Gregory Renza with RBC Capital. Your line is open.

Gregory Renza (Senior Biotechnology Analyst)

Great. Thanks. Good morning, Alex and team.

Alex Sapir (CEO and President)

Morning, Greg.

Gregory Renza (Senior Biotechnology Analyst)

The updates. And thank you. And thanks for taking the questions. Just a couple from us, Alex. Just as you reflect on the Losmapimod experience, how are you using that journey to inform the value proposition, the risk assessment of future programs, not just with pociredir, but also, of course, with the early discovery programs? And then maybe secondly, if you could just comment a bit about how you expect to balance the early discovery programs internally and with CAMP4 that you're looking at versus the thought of looking externally for assets. And maybe I'll sneak a third one, if I may, for Alan, maybe related to all this as you've talked a bit about resources and spend for 2025. How does that allocation pan out? How should we be thinking about what's implied in some of the runway there? Thanks so much, guys.

Alex Sapir (CEO and President)

Yeah. Thanks so much, Greg. Great, great, great set of questions. Yeah. So I think if we do a comparison and contrast of losmapimod versus pociredir, I think they are very different. I think some of the challenges that we knew going into the phase III study with losmapimod is it was a new and novel endpoint, and it was very effort-dependent. I think what we see with pociredir and what we know about pociredir in terms of the patients that were enrolled in the study prior to the initiation of the hold and very impressive increases that we saw in fetal hemoglobin, as well as the abundance of literature out there to show that increases in fetal hemoglobin have a direct impact on patients' crises as well as their overall survival.

I think I see them as very sort of different development programs as we move forward. I think, as I mentioned earlier after one of Pat's last comments, we are having internal discussions. Given how strong the evidence is, we've been working very closely with some ex-FDA consultants to really understand, does it make sense or when is the right time to approach the agency and their surrogate endpoint group within the agency around the potential to use fetal hemoglobin as a surrogate endpoint. Obviously, the agency does have a history of approving other products in sickle cell disease using surrogate endpoints as we know. I think as you think about sort of early discovery versus externally, as Alan mentioned, we've got a very robust balance sheet into at least 2027, and that is assuming success with all of our programs.

That's advancing the pociredir program once we've completed this phase I-B study into phase II and phase III. We certainly have the financial ability to go out and look at external assets. I think we've got a lot of really exciting things going on in early discovery. If we were to look externally at potentially opportunities to bring in-house, given how robust our balance sheet is, we'll continue to be very judicious and highly selective. The company has had a history of doing deals, but those deals, I think, have been on excellent terms, and we've been very sort of smart and judicious in terms of what we decide to bring in.

So if we were to do something, I think it would be at the level of sort of intelligence and just sort of deep diligence that we've historically done with other licensing opportunities of assets that we brought in. And then maybe Alan to answer his third question.

Alan Musso (CFO)

Yeah, Alex, I think you addressed some of it. Greg, as we guided, we expect next year's spend to be $55 million-$65 million, and that does anticipate full funding of pociredir and maximizing the opportunity there and funding our pre-clinical programs and seeing those advance forward. So we feel like we're fortunate to be in a really good shape with our cash position at this time.

Gregory Renza (Senior Biotechnology Analyst)

Great. Thank you, guys.

Alex Sapir (CEO and President)

Yeah. Thanks, Greg.

Operator (participant)

And our next question comes from Joseph Schwartz with Leerink. Your line is open.

Joori Park (VP Equity Research)

Hi. I'm Joori Park, dialing in for Joe. Thanks for taking our question. So this summer at EHA, you presented a map of sites you were onboarding, and I believe there were 11 in the U.S. and two ex-U.S. I was curious what your latest thoughts were on these sites. And separately, I believe that you plan to activate up to 20 sites. That's what you said on a previous call with more sites to activate, which you've mentioned on today's call. So I was curious if you've identified the remaining seven sites and where you are on the onboarding process for them. Thank you.

Alex Sapir (CEO and President)

Yeah. It's a great question. And I'll start, and then I'll turn it over to Pat to provide a little bit more detail. So yes, you are correct. We have 12 sites activated. I would say that some of the more recently activated sites, both here in the U.S. as well as the ex-U.S., are absolutely the right sites that are in place now. And again, pleased with some of the early insights we're seeing in terms of patient enrollment. Our goal is still to ramp up and enroll 20 sites by the end of this year. Both Pat and I were at an investigator meeting in Dallas just this past Friday. We had 15 sites represented, many of the existing sites, but also several new sites that will be activated in the coming months.

But maybe Pat, do you want to sort of give a little bit more specificity in terms of when we would expect to have those additional sites onboarded?

Pat Horn (CMO)

Yeah, so we are actively working on activation, and to your question, we have identified the sites that we believe will be successful in recruiting Pioneer. The majority of those remain in the U.S., but there are some in Africa, and we are working to activate all of those. We have activated, I don't know the exact number, but many more since the EHA meeting, and we continue. We have in the next couple of months, we have the activation and site initiation visits planned for pretty much the remaining sites. We continue to just, and like I said, we think these sites will be sufficient to enroll Pioneer. We continue to engage new sites and new investigators, partly for future studies because there has been an increased interest in pociredir and hemoglobin F inducers, so we continue to engage with new sites.

There's a possibility that some of them, if their activation could be quick enough, could also join and help with Pioneer. It's predominantly more for future studies.

Joori Park (VP Equity Research)

Great. Thank you.

Alex Sapir (CEO and President)

Yeah. Thanks so much for the question.

Operator (participant)

As a reminder to ask a question, please press star one one on your telephone and wait for your name to be announced. And our next question comes from Corinne Johnson with Goldman Sachs. Your line is open.

Corinne Johnson (Managing Director)

Good morning, everyone. You mentioned that the pociredir program is fully funded. I guess, does that apply to a broader scope of patients than is currently allowed within the trial, or would that be specific to this higher risk group you're currently focused on? Thanks.

Alex Sapir (CEO and President)

Yeah. So Corinne, maybe I'll start, and then I'll turn it over to Alan for more specifics in terms of the funding and what we've allocated. Yeah. So as we've said in the past, we believe that once we're able to show the benefits that based on the data that we had prior to the initiation of the hold with these additional 20 patients, we will be able to have a future conversation with the agency, as Pat mentioned, at the end of the phase I program to really look to expand the patient population beyond the more severe patient population that we're currently targeting. Because I think, obviously, for the agency, they're thinking about everything from a risk-benefit. And as we've talked about in some of our pre-clinical work, there was this carcinogenicity risk that was seen.

That was really the impetus for the reason for the hold. But there were also some of the impressive levels of fetal hemoglobin that we saw in the first 15 patients. So our goal is to get these additional 20 patients with this more severe patient population enrolled, have them complete their entire three months of dosing, take a look at that data, and then approach the agency about expanding the patient population beyond where we are today. And then Alan, in terms of the specifics around the funding and what that looks like and what the study looks like.

Alan Musso (CFO)

Yeah, Corinne, so our sort of budgeting and forecast process encompasses taking the development plans and in full as to where we expect the program will go, not only next year, but beyond that, and then allocating the capital towards that, so that's the guidance that we give, which is sort of complete development anticipation for pociredir going forward.

Corinne Johnson (Managing Director)

Thank you.

Alan Musso (CFO)

Thanks, Corinne.

Operator (participant)

I show no further questions at this time. This does conclude today's conference call. Thank you so much for participating. You may now disconnect.